Researchers continue to excited about the medication , a innovative dual agonist showing promising data in early trials for size loss . It acts by impacting two systems: GLP-1 and GIP, that , when https://sachinskps973485.ourcodeblog.com/41173659/a-new-prospect-for-size-reduction